Literature DB >> 8664346

Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family.

C M Bunce1, J C Mountford, P J French, D J Mole, J Durham, R H Michell, G Brown.   

Abstract

HL60 cells are human promyeloid cells that can be induced to differentiate by physiological stimuli (e.g. all-trans retinoic acid (ATRA), 1 alpha,25-dihydroxyvitamin D3 (D3), granulocyte colony-stimulating factor (G-CSF)) and by non-physiological agents such as dimethysulphoxide (DMSO) and protein kinase C-activating phorbol esters. The sensitivity of HL60 cells to physiological differentiating agents, but not to DMSO, is enhanced when cells are exposed to 'anti-inflammatory agents' (e.g. indomethacin) or are 'primed' (pretreated) with a small amount of ATRA: alone, neither treatment induces differentiation. We earlier suggested that indomethacin might act by inhibiting the endogenous formation of a differentiation-suppressing prostanoid (Bunce, C.M., et al. (1994) Leukemia 8, 595-604). Studies of the formation of prostanoids by HL60 cells and of the effects of prostanoids on these cells failed to identify any prostanoid that could be implicated in sensitization by indomethacin. 3 alpha-Hydroxysteroid dehydrogenase (3 alpha-HSD) is another target of such 'anti-inflammatory agents'. Steroid inhibitors of 3 alpha-HSD sensitized HL60 cells to inducers of differentiation in a manner similar to indomethacin. 3 alpha-HSD is a member of the aldoketoreductase enzyme family, which comprises many enzymes of similar size and primary sequence. A protein that was recognised by an antiserum to 3 alpha-HSD was found in HL60 cells, but the cells showed no detectable 3 alpha-HSD activity. The 3 alpha-HSD-like protein was strikingly down-regulated by 'priming' doses of ATRA. When treatment with a differentiation-sensitizing 'anti-inflammatory agent' or steroid was combined with ATRA "priming', the effects of the different treatments were not additive: the resulting increase in sensitivity equalled that achievable by either treatment alone. We conclude that interference with a single intracellular regulatory mechanism underlies the increases in sensitivity of cells to differentiating agents that are caused by anti-inflammatory agents, by certain steroids and by 'priming' with ATRA. Decreased activity of a yet-to-be-identified member of the aldoketoreductase family of dehydrogenases is likely to be a central feature of a previously unrecognised mechanism that controls the responsiveness of cells to environmental stimuli such as retinoids and D3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664346     DOI: 10.1016/0167-4889(96)00005-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Sodium salicylate-triggered apoptosis in HL-60 cells depends on caspase-8 activation.

Authors:  Xiequn Chen; Youfeng Wan; Qingxian Bai; Weiping Zhang; Huafeng Zhu
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

2.  Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity.

Authors:  S N Kang; S H Kim; S W Chung; M H Lee; H J Kim; T S Kim
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 3.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

4.  Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

Authors:  Farhat L Khanim; Rachel E Hayden; Jane Birtwistle; Alessia Lodi; Stefano Tiziani; Nicholas J Davies; Jon P Ride; Mark R Viant; Ulrich L Gunther; Joanne C Mountford; Heinrich Schrewe; Richard M Green; Jim A Murray; Mark T Drayson; Chris M Bunce
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

5.  Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling.

Authors:  Farnaz Jamshidi; Jing Zhang; Jonathan S Harrison; Xuening Wang; George P Studzinski
Journal:  Cell Cycle       Date:  2008-01-14       Impact factor: 4.534

6.  Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.

Authors:  Alessia Lodi; Stefano Tiziani; Farhat L Khanim; Mark T Drayson; Ulrich L Günther; Christopher M Bunce; Mark R Viant
Journal:  ACS Chem Biol       Date:  2010-10-18       Impact factor: 5.100

7.  Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.

Authors:  Pedro Veliça; Nicholas J Davies; Pedro P Rocha; Heinrich Schrewe; Jonathan P Ride; Chris M Bunce
Journal:  Mol Cancer       Date:  2009-12-14       Impact factor: 27.401

8.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12

9.  Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines.

Authors:  Stefano Tiziani; Alessia Lodi; Farhat L Khanim; Mark R Viant; Christopher M Bunce; Ulrich L Günther
Journal:  PLoS One       Date:  2009-01-22       Impact factor: 3.240

10.  Malonate as a ROS product is associated with pyruvate carboxylase activity in acute myeloid leukaemia cells.

Authors:  Farhat L Khanim; Ulrich L Günther; Michelle A C Reed; Christian Ludwig; Christopher M Bunce
Journal:  Cancer Metab       Date:  2016-08-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.